Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | VNN1 | O95497 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605176 | 0.93 | KMO (0.47) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 | |
| SCHEMBL1605154 | 0.92 | ELANE (0.47) | CYP11B2CYP11B1CYP17A1CYP19A1ELANE | |
| SCHEMBL1605777 | 0.90 | ABL1 (0.52) | CYP11B2CYP11B1CYP17A1GRM5ABL1 | |
| SCHEMBL1605663 | 0.89 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 | |
| SCHEMBL1606203 | 0.88 | CYP11B2 (0.46) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 | |
| SCHEMBL1606243 | 0.88 | CYP11B2 (0.44) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 | |
| SCHEMBL1605932 | 0.88 | CYP11B2 (0.46) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 | |
| SCHEMBL1605020 | 0.87 | NR1H2 (0.42) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 | |
| SCHEMBL1607108 | 0.86 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 | |
| SCHEMBL12732932 | 0.85 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP17A1CHRNB2CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104193725-B | Organic compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | claimed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | claimed |
| CN-104193725-B | Organic compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242963-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150210672-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288126-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| EP-2307371-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20110082129-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-07 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261698-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156462-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082129-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885CYP11B1 14/4885CYP17A1 65/4885 |
| US-20100261698-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 13/4885CYP11B1 14/4885CYP17A1 65/4885 |
| US-20150210672-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885CYP11B1 15/4885CYP17A1 57/4885 |
| US-20140288126-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | CYP11B2 12/4885CYP11B1 15/4885CYP17A1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.